Welcome to our dedicated page for Preveceutical news (Ticker: PRVCF), a resource for investors and traders seeking the latest updates and insights on Preveceutical stock.
PreveCeutical Medical Inc. develops health-science programs for preventive and curative therapies using organic and nature-identical products. The company's recurring updates cover research and intellectual property for its Sol-gel Program, Nature Identical™ peptides, non-addictive analgesic peptides, CNS-active agent delivery, concussion-related therapeutics, and gene-therapy work associated with diabetes and obesity.
PRVCF news also includes patent filings and patent-office actions, board and subsidiary governance changes, developments involving BioGene Therapeutics as a company in which PreveCeutical holds a significant interest, and Canadian venture-issuer reporting matters such as its move to semi-annual financial reporting.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.